
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
University of Minnesota Cancer Center [S. S. H., M. Y., S. G. C.] and Division of Environmental and Occupational Health, School of Public Health [A. F., J. L. A., I. A. G., T. R. C., A. D. R., S. J. M., K. S.], University of Minnesota, Minneapolis, Minnesota 55455
| Abstract |
|---|
|
|
|---|
5 ng/ml. NNAL or NNAL-Gluc was detected in 52 of 54 samples with total cotinine
5 ng/ml and in 10 of 20 samples with total cotinine <5 ng/ml. Levels of NNAL plus NNAL-Gluc and total cotinine were significantly higher when exposure to ETS was reported than when no exposure was reported. However, even when no exposure to ETS was reported, levels of NNAL, NNAL-Gluc, and NNAL plus NNAL-Gluc were higher than in children with documented low exposure to ETS, as determined by cotinine levels <5 ng/ml. Levels of NNAL, NNAL-Gluc, and cotinine were not significantly different in samples collected twice from the same children at 3-month intervals. Levels of NNAL plus NNAL-Gluc in this study were comparable with those observed in our previous field studies of adults exposed to ETS. There was a 93-fold range of NNAL plus NNAL-Gluc values in the exposed children. The results of this study demonstrate widespread and considerable uptake of the tobacco-specific lung carcinogen NNK in this group of elementary school-aged children, raising important questions about potential health risks. Our data indicate that objective biomarkers of carcinogen uptake are important in studies of childhood exposure to ETS and cancer later in life. | Introduction |
|---|
|
|
|---|
20% increase in risk for lung cancer in ETS-exposed adults (2)
. This is considerably less than the 10002000% increase in risk for lung cancer seen in smokers, but the uptake of tobacco smoke constituents in nonsmokers is also far less than in smokers. Epidemiological investigations of childhood exposure to ETS and adult lung cancer have not produced consistent results. In a recent meta-analysis, the authors concluded that there was no increased risk but cautioned that the presence of some positive studies argues against concluding that there is no relationship (8) . It is biologically plausible that children exposed to carcinogens in ETS could be at risk for cancer later in life. However, the extent of tobacco constituent uptake by children has not been quantified in any epidemiological study of childhood exposure and lung cancer risk.
Our goal in this study was to investigate the uptake by elementary school-aged children (grades 25) of the lung carcinogen NNK (Fig. 1)
. NNK is a potent pulmonary carcinogen in rodents and may play a significant role as a cause of lung cancer in smokers (9, 10, 11)
. NNK uptake can be quantified by analysis of two metabolites, NNAL and NNAL-Gluc, in urine (Fig. 1
; Ref. 12
). Because NNK is found only in tobacco products, the presence of NNAL and NNAL-Gluc in urine is a specific biomarker of tobacco carcinogen exposure (9)
. We have demonstrated previously the presence of these NNK metabolites in the urine of adult nonsmokers exposed to ETS, but there have been no reports of NNK uptake by ETS-exposed children (13, 14, 15)
. Although numerous studies have measured levels of the nicotine metabolite cotinine in blood, urine, saliva, and hair of ETS-exposed children, there are scant data on tobacco carcinogen uptake by children (16)
. Higher levels of polycyclic aromatic hydrocarbon-albumin adducts and 4-aminobiphenyl-hemoglobin adducts have been observed in ETS-exposed versus unexposed children (17
, 18)
. Comparisons of NNAL and NNAL-Gluc levels in children and adults exposed to ETS could provide an index of their relative uptake of NNK, perhaps resulting in additional insights concerning lung cancer risk. The children in this study were part of the SHIELD study, a novel school-based investigation of the environmental health of children in economically disadvantaged neighborhoods of Minneapolis (19)
.
|
| Materials and Methods |
|---|
|
|
|---|
1 to either of these questions, the child was considered exposed to ETS. We also asked about other exposures, as follows: (a) on average for the past month, what was the number of minutes or hours per week the child spent in a car, bus, van, or other enclosed vehicle with anyone who was smoking tobacco; and (b) on average for the past month, what was the number of minutes or hours per week the child spent in any other indoor or enclosed location with anyone who was smoking tobacco. Positive answers to these questions were taken to indicate exposure to ETS. Urine samples were obtained at school under the supervision of the school nurse. Organic fruit juices were provided to the children at the start of the school day to increase the volume of the urine samples. Urine was collected in 4-oz polypropylene containers.
Laboratory Analyses.
Total cotinine [cotinine plus pyridyl-N-ß-D-glucopyranuronosyl-(S)-(-)-cotininium inner salt] was measured by gas chromatography-mass spectrometry, as described (20)
. All of the usable samples with total cotinine
10 ng/ml as well as a selection of those with total cotinine <10 ng/ml were analyzed for NNAL and NNAL-Gluc. This approach was taken to conserve time and resources, because the NNAL and NNAL-Gluc assay is more labor intensive than the total cotinine assay. The 10 ng/ml cotinine value was chosen to indicate potentially high exposure to ETS. NNAL and NNAL-Gluc were quantified by GC-TEA, using modifications of methods described previously (13
, 14)
. Urine (20 ml) in a 50-ml disposable glass centrifuge tube (Kimble, Vineland, NJ) was adjusted to pH 7.0 ± 0.5. The sample was partitioned three times with equal volumes of ethyl acetate. The samples were shaken gently on a bench top shaker (Glas-Col, Terre Haute, IN) for 510 min, and any resulting emulsions were reduced by low speed centrifugation. The combined ethyl acetate extracts were placed in a 4-oz amber bottle, and 1 ng of iso-NNAL internal standard, dissolved in acetonitrile, was added along with
5 g of sodium sulfate. The mixture was briefly shaken. After
0.5 h, the ethyl acetate extract containing the free NNAL was transferred to a new 50-ml centrifuge tube and concentrated to dryness in portions on a model SVT200H SpeedVac centrifugal concentrator (Savant Instruments, Farmingdale, NY) and stored at -20°C until HPLC cleanup. The extracted urine containing NNAL-Gluc was reduced to approximately two-thirds of its original volume in the SpeedVac to remove residual ethyl acetate, which may inhibit ß-glucuronidase activity. This concentrated urine was treated with 25,000 units of ß-glucuronidase type IX-A from Escherichia coli (Sigma Chemical Co., St. Louis, MO), and the solution was incubated overnight with gentle shaking at 37°C. The pH was adjusted to 7.0 ± 0.5, 1 ng of iso-NNAL was added, and the urine was extracted three times with equal volumes of methylene chloride. The methylene chloride extracts containing NNAL released from NNAL-Gluc were dried with sodium sulfate and concentrated to dryness in the same manner used for the ethyl acetate extracts.
The residue of the ethyl acetate extract was transferred with 400 µl of potassium phosphate buffer (pH 7.0) 0.1 M (prepared from 0.1 M KH2PO4 adjusted to pH 7 with H3PO4) and 500 µl of H2O to an autosampler vial. The residue of the methylene chloride layer was similarly transferred with 50 µl of methanol, 400 µl potassium phosphate buffer 0.1 M (pH 7.0) and 450 µl of H2O. Ten µl of an aqueous solution of the collection markers consisting of 50 µg 2-pyridylcarbinol acetate and 50 µg of 3-acetylpyridine were added to each vial. The HPLC eluant was monitored at 254 nm, and the fraction between the apices of the two marker compounds was collected. The column used was a 150 mm x 4.6 mm Bondclone C18 (Phenomenex, Torrance, CA) with a flow rate of 1 ml/min. Solvent "A" was H2O and solvent "B" was methanol. The solvent program was as follows: a linear gradient from 90% to 55% A over 20 min, then to the initial composition over 2 min, then re-equilibration for 15 min. The collection markers eluted at
11 and
16 min. The fraction containing NNAL and iso-NNAL was collected in a 15-ml glass centrifuge tube (Kimble) and was concentrated to dryness on the SpeedVac.
For normal phase cleanup, the residue from the reverse-phase HPLC collection was dissolved in 200 µl of ethyl acetate containing 5% isopropyl alcohol. 3-Pyridylpropanol (0.5 µg) was added as a collection marker. The column was a 250 mm x 4.0 mm Luna 5 µ silica column (Phenomenex), which was used at a flow rate of 1 ml/min. The solvent system was isocratic: 82% chloroform and 18% isopropyl alcohol. The NNAL/iso-NNAL fraction was collected starting just after the marker peak eluted. The collection ended 8 min later. The collected material was concentrated to dryness using the SpeedVac.
The residue was transferred with methanol to a microvial (Kimble) and was brought to dryness using the SpeedVac. Five µl of 99% bis-trimethylsilyltrifluoroacetamide containing 1% trimethylchlorosilane (Regis Technologies, Morton Grove, IL) was added. N-Nitrosopentyl-3-picolylamine (TRC, North York, Ontario) was added to each vial as an injection standard at a final concentration of 0.40 ng/µl. The vials were capped, heated at 50°C for 60 min, and mixed intermittently. Four µl were injected in the pulse splitless mode on the GC-TEA from a cooled autosampler tray. The GC-TEA consisted of a HP 6890 gas chromatograph (Agilent Technologies, Wilmington, DE) interfaced to a model 543 Thermal Energy Analyzer (Orion Research, Beverly, MA). The pyrolyzer of the TEA and interface temperatures were 500 and 275°C, respectively. The separation was performed on a 30 m x 0.32 mm ID, 0.25-µm film thickness, DB-1701 column (Agilent Technologies) attached to a 2 m x 0.32 mm ID deactivated retention gap. The injection port temperature was 225°C. A pressure program was used to keep the flow rate of helium at a constant 2.6 ml/min. The oven temperature was initially held at 80°C for 2 min and was then ramped to 180°C at 20°/min. It was then ramped to 210°C at 2°C/min. From 210°C it was increased to 250°C at 20°C/min and held for 5 min.
GC-MS/MS was carried out as described (14) .
Statistical Analysis and Related Considerations.
Children were sampled with probabilities specific to strata defined by school, grade, ethnicity, and sex, so all of the analyses were weighted to account for these probabilities and for nonresponse. Furthermore, if a child with siblings in the school was selected, all of the siblings were selected as well. Because children in the same family had correlated exposures, all of the analyses accounted for this correlation. Because only a fraction of urine samples with cotinine level <10 ng/ml were analyzed for NNAL and NNAL-Gluc levels, there were different selection probabilities depending on cotinine level. Thus, analyses were additionally weighted for these different sampling rates. Analyses were performed on log-transformed laboratory values to correct for skewness in the distributions, and transformed means were exponentiated to obtain geometric means. Confidence intervals were calculated in the transformed scale and back-transformed by taking logs.
A randomization test using the weighted means and preserving the family grouping was used to compare total cotinine and NNK metabolite levels in the urine of children with reported ETS exposure to those of children with no reported ETS exposure. In the one instance where siblings reported different exposures, the index childs exposure was used for the family. To compare February and May values, a randomization test using weighted means that preserved pairing and family grouping was used. Correlations between repeated laboratory measurements were estimated and tested by weighted linear models.
On the basis of previous data in the literature, subjects with <5 ng/ml total cotinine in their urine were not aware of any ETS exposure (21 , 22) . Thus, for analyses relating NNAL and NNAL-Gluc levels to total cotinine levels, a cutoff of 5 ng/ml total cotinine was used to indicate potential ETS exposure. In agreement with these data, a recent study found mean total cotinine levels in nonsmoking men and their spouses, who reported no ETS exposure, to be 2.2 ± 3.1 ng/ml urine (15) . Tests of NNAL detection fraction by these cotinine strata were performed using weighted log-linear models.
| Results |
|---|
|
|
|---|
Seventy of the 204 children (34.3%) had total cotinine levels
5 ng/ml urine. The distribution of total cotinine values is illustrated in Fig. 2
. The mean level of total cotinine in the initial samples with amounts
5 ng/ml urine was 25.5 ± 22.6 (SD) ng/ml. Among the 95 children for whom urine samples were available in both February and May, 38 (40.0%) had total cotinine levels
5 ng/ml in February. Of these, 24 also had total cotinine
5 ng/ml in May. There was no significant difference between levels of total cotinine in the urine of these children in February versus May (paired t test). The correlation of total cotinine levels in individual children in February and May was 0.703 (P < 0.0001).
|
Typical GC-TEA traces from samples of urine positive for NNAL and NNAL-Gluc in children are illustrated in Fig. 3
. The identities of NNAL and NNAL-Gluc were confirmed by GC-MS/MS of selected samples (Fig. 4)
. Both types of analysis showed clear peaks for NNAL-trimethylsilyl ether.
|
|
5 ng/ml and in 10 of 20 samples in which total cotinine was <5 ng/ml. Thus, detection of NNAL or NNAL-Gluc was significantly more likely when total cotinine was
5 ng/ml than when it was <5 ng/ml (P < 0.0001). When exposure to ETS was reported by questionnaire, NNAL or NNAL-Gluc was detected in 35 of 38 samples, whereas it was detected in 26 of 35 samples in which no exposure was reported. Total cotinine was
5 ng/ml in 34 of 38 samples from children having reported exposure to ETS and in 20 of 35 samples with no reported exposure. Exposure data were not available for 1 child.
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
More than 34% of the 204 children had urinary total cotinine
5 ng/ml. Among the samples with
5 ng/ml total cotinine, which were also analyzed for NNAL and NNAL-Gluc, 96.2% were positive for these carcinogen metabolites. But surprisingly, 10/20 (50%) of samples in which total cotinine levels were <5 ng/ml were also positive for NNAL or NNAL-Gluc. The mean level of NNAL plus NNAL-Gluc in these 20 samples was 0.016 ± 0.030 pmol/ml urine. We did not analyze all of the samples for NNAL and NNAL-Gluc, but extrapolation of our results suggests that 134 of 204 (66%) of the children would have positive NNAL or NNAL-Gluc levels. The more frequent detection of NNAL and NNAL-Gluc than of total cotinine may relate to differences in the pharmacokinetics of these metabolites. We have shown previously that the decay of NNAL and NNAL-Gluc from urine is slow after cessation of smoking (t1/2
, 34 days; t1/2ß, 4045 days) compared with rapid disappearance of total cotinine (20)
. Therefore, the probability of detecting NNAL or NNAL-Gluc after a given exposure to tobacco smoke may be greater than that of detecting cotinine. The widespread occurrence of NNAL and NNAL-Gluc in the urine of elementary school-aged children is a cause for concern.
There was consistency in our data, as indicated by comparisons of the NNAL and NNAL-Gluc levels in 16 children sampled in both February and May (Table 3)
. There were no significant differences in these biomarkers at the two different sampling times. There were also no significant differences between total cotinine levels in 95 children who were sampled at both times.
Levels of NNAL, NNAL plus NNAL-Gluc, and total cotinine were significantly higher in the urine of children classified as "exposed to ETS" than in the urine of children classified as "unexposed," based on questionnaire data. However, substantial amounts of NNAL plus NNAL-Gluc were detected even in the urine of nominally unexposed children. The mean level of NNAL plus NNAL-Gluc in these children was 0.035 ± 0.058 pmol/ml urine, which was substantially greater than in the urine of children with cotinine <5 ng/ml (0.016 ± 0.030 pmol/ml). The level of NNAL plus NNAL-Gluc in these supposedly unexposed children can be compared with a level of 0.050 ± 0.068 in the urine of women who live with smokers (Table 4
; Ref. 15
). These amounts are about 23% of the levels typically found in smokers.
|
NNAL plus NNAL-Gluc correlated with total cotinine in this study (Fig. 5)
. The correlation coefficient, r = 0.71, was similar to that in 223 smokers, r = 0.68, in which total cotinine and NNAL plus NNAL-Gluc were determined by essentially the same methods used here (10)
. We have not observed this correlation in all of our ETS studies (Table 4)
but that may be attributable to the relatively small numbers of subjects in some of the studies. Collectively, the data strongly indicate that total cotinine and NNAL plus NNAL-Gluc are uptake biomarkers. Total cotinine is a biomarker of nicotine uptake, whereas NNAL plus NNAL-Gluc is a biomarker for uptake of NNK, a lung carcinogen. It is unclear whether total cotinine would be a good surrogate for NNAL plus NNAL-Gluc, because NNAL plus NNAL-Gluc are generally longer-lived biomarkers.
In summary, the results of this study demonstrate considerable uptake of the tobacco-specific lung carcinogen NNK in this group of elementary school-aged children. Although it is difficult to quantify the public health risk this uptake represents, it is potentially larger than acceptable. Our results indicate that biomarkers of carcinogen uptake should be incorporated into studies of childhood exposure to ETS and cancer development later in life.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 This study was supported by National Cancer Institute Grant CA-81301 and Science to Achieve Results Grants R825813 and R826789 from the United States Environmental Protection Agency. The Shared Resources are supported in part by National Cancer Institute Cancer Center Support Grant CA-77598. ![]()
2 To whom requests for reprints should addressed, at University of Minnesota Cancer Center, Mayo Mail Code 806, 420 Delaware Street S.E., Minneapolis, MN 55455. E-mail: hecht002{at}umn.edu ![]()
3 The abbreviations used are: ETS, environmental tobacco smoke; GC-MS/MS, gas chromatography-tandem mass spectrometry; GC-TEA, gas chromatography-nitrosamime selective detection; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NNAL-Gluc, 4-(methylnitrosamino)-1-(3-pyridyl)-1-(O-ß-D-glucopyranuronosyl)butane [some of the pyridine-N-glucuronide, 4-(methylnitrosamino)-1-(3-pyridyl-N-ß-D-glucopyranuronosyl)-1-butanolonium inner salt, may also be present]; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; SHIELD, School Health Initiative: Environment, Learning, Disease; HPLC, high-performance liquid chromatography; ID, inner diameter. ![]()
Received 4/20/01; revised 7/27/01; accepted 9/11/01.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
I. Stepanov and S. S. Hecht Detection and Quantitation of N'-Nitrosonornicotine in Human Toenails by Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 945 - 948. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Stark, K. Rohde, J. E. Maher, B. A. Pizacani, C. W. Dent, R. Bard, S. G. Carmella, A. R. Benoit, N. M. Thomson, and S. S. Hecht The Impact of Clean Indoor Air Exemptions and Preemption Policies on the Prevalence of a Tobacco-Specific Lung Carcinogen Among Nonsmoking Bar and Restaurant Workers Am J Public Health, August 1, 2007; 97(8): 1457 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Stepanov, S. S. Hecht, B. Lindgren, P. Jacob III, M. Wilson, and N. L. Benowitz Relationship of Human Toenail Nicotine, Cotinine, and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol to Levels of These Biomarkers in Plasma and Urine Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1382 - 1386. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Ginzel, G. S. Maritz, D. F. Marks, M. Neuberger, Jim. R. Pauly, J. R. Polito, R. Schulte-Hermann, and T. A. Slotkin Critical Review: Nicotine for the Fetus, the Infant and the Adolescent? J Health Psychol, March 1, 2007; 12(2): 215 - 224. [Abstract] [PDF] |
||||
![]() |
I. Stepanov, R. Feuer, J. Jensen, D. Hatsukami, and S. S. Hecht Mass Spectrometric Quantitation of Nicotine, Cotinine, and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol in Human Toenails Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2378 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Hecht, S. G. Carmella, K.-A. Le, S. E. Murphy, A. J. Boettcher, C. Le, J. Koopmeiners, L. An, and D. J. Hennrikus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides in the urine of infants exposed to environmental tobacco smoke. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 988 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Stepanov, S. S. Hecht, G. Duca, and I. Mardari Uptake of the Tobacco-Specific Lung Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-Butanone by Moldovan Children Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 7 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y S Lin, L L Kupper, and S M Rappaport Air samples versus biomarkers for epidemiology Occup. Environ. Med., November 1, 2005; 62(11): 750 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. E. Tulunay, S. S. Hecht, S. G. Carmella, Y. Zhang, C. Lemmonds, S. Murphy, and D. K. Hatsukami Urinary Metabolites of a Tobacco-Specific Lung Carcinogen in Nonsmoking Hospitality Workers Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1283 - 1286. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Vineis, L Airoldi, F Veglia, L Olgiati, R Pastorelli, H Autrup, A Dunning, S Garte, E Gormally, P Hainaut, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study BMJ, February 5, 2005; 330(7486): 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Breyer-Pfaff, H.-J. Martin, M. Ernst, and E. Maser ENANTIOSELECTIVITY OF CARBONYL REDUCTION OF 4-METHYLNITROSAMINO-1-(3-PYRIDYL)-1-BUTANONE BY TISSUE FRACTIONS FROM HUMAN AND RAT AND BY ENZYMES ISOLATED FROM HUMAN LIVER Drug Metab. Dispos., September 1, 2004; 32(9): 915 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
S S Hecht Carcinogen derived biomarkers: applications in studies of human exposure to secondhand tobacco smoke Tob. Control, March 1, 2004; 13(90001): i48 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Anderson, J. Kliris, L. Murphy, S. G. Carmella, S. Han, C. Link, R. L. Bliss, S. Puumala, S. E. Murphy, and S. S. Hecht Metabolites of a Tobacco-Specific Lung Carcinogen in Nonsmoking Casino Patrons Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1544 - 1546. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Carmella, S. Han, A. Fristad, Y. Yang, and S. S. Hecht Analysis of Total 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) in Human Urine Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1257 - 1261. [Abstract] [Full Text] |
||||
![]() |
A. J. Alberg, G. B. Diette, and J. G. Ford Invited Commentary: Attendance and Absence as Markers of Health Status--The Example of Active and Passive Cigarette Smoking Am. J. Epidemiol., May 15, 2003; 157(10): 870 - 873. [Full Text] [PDF] |
||||
![]() |
S. S. Hecht Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer Carcinogenesis, June 1, 2002; 23(6): 907 - 922. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |